M. C. Fidan Et Al. , "Real-World Efficacy and Safety of Tyrosine Kinase Inhibitors in Patients With Advanced Bone Sarcomas: The TOGBONE Study of the Turkish Oncology Group," JCO Global Oncology , vol.12, no.9, 2026
Fidan, M. C. Et Al. 2026. Real-World Efficacy and Safety of Tyrosine Kinase Inhibitors in Patients With Advanced Bone Sarcomas: The TOGBONE Study of the Turkish Oncology Group. JCO Global Oncology , vol.12, no.9 .
Fidan, M. C., Keskin Uzundere, F., Biter, S., Durnalı, A., Kalacı, E., ODABAŞI BÜKÜN, H., ... Kocaaslan, E.(2026). Real-World Efficacy and Safety of Tyrosine Kinase Inhibitors in Patients With Advanced Bone Sarcomas: The TOGBONE Study of the Turkish Oncology Group. JCO Global Oncology , vol.12, no.9.
Fidan, Mehmet Et Al. "Real-World Efficacy and Safety of Tyrosine Kinase Inhibitors in Patients With Advanced Bone Sarcomas: The TOGBONE Study of the Turkish Oncology Group," JCO Global Oncology , vol.12, no.9, 2026
Fidan, Mehmet C. Et Al. "Real-World Efficacy and Safety of Tyrosine Kinase Inhibitors in Patients With Advanced Bone Sarcomas: The TOGBONE Study of the Turkish Oncology Group." JCO Global Oncology , vol.12, no.9, 2026
Fidan, M. C. Et Al. (2026) . "Real-World Efficacy and Safety of Tyrosine Kinase Inhibitors in Patients With Advanced Bone Sarcomas: The TOGBONE Study of the Turkish Oncology Group." JCO Global Oncology , vol.12, no.9.
@article{article, author={Mehmet Cem Fidan Et Al. }, title={Real-World Efficacy and Safety of Tyrosine Kinase Inhibitors in Patients With Advanced Bone Sarcomas: The TOGBONE Study of the Turkish Oncology Group}, journal={JCO Global Oncology}, year=2026}